<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39328629</PMID><DateRevised><Year>2024</Year><Month>09</Month><Day>28</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2168-8184</ISSN><JournalIssue CitedMedium="Print"><Volume>16</Volume><Issue>8</Issue><PubDate><Year>2024</Year><Month>Aug</Month></PubDate></JournalIssue><Title>Cureus</Title><ISOAbbreviation>Cureus</ISOAbbreviation></Journal><ArticleTitle>Impact of HLA Alleles on COVID-19 Severity in Kidney Transplant Recipients: A Single-Center Study.</ArticleTitle><Pagination><StartPage>e67881</StartPage><MedlinePgn>e67881</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">e67881</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.7759/cureus.67881</ELocationID><Abstract><AbstractText>Introduction The coronavirus disease 2019 (COVID-19) pandemic has significantly impacted global health, particularly affecting vulnerable populations, such as organ transplant recipients. Human leukocyte antigens (HLAs) play a critical role in immune response regulation, and understanding their association with COVID-19 can provide insights into disease susceptibility and severity. This study aims to explore the association between HLA allele variability and COVID-19 susceptibility and severity among kidney transplant recipients. Methods In 2023, we conducted a study on 73 kidney transplant recipients who tested positive for COVID-19 via polymerase chain reaction. This study included assessments of clinical status, immunosuppressive drug levels, HLA allele frequencies, and donor-recipient tissue compatibility. Molecular analyses were performed using sequence-specific oligonucleotide typing, and statistical analysis was conducted using IBM SPSS Statistics, version 20.0 (IBM Corp., Armonk, NY). Results Among the participants, 31 were hospitalized and 42 were treated as outpatients. Significant differences were observed in HLA allele distributions, particularly the HLA-A*11 allele, which was more prevalent in outpatient-treated patients, suggesting a potential protective effect. No significant age differences were observed between hospitalized and outpatient groups. Serum tacrolimus levels were notably higher in outpatients. Statistical analyses revealed significant associations between certain HLA groups and the severity of COVID-19 infection. Conclusions This study highlights the importance of HLA allele compatibility in influencing the clinical outcomes of COVID-19 in kidney transplant recipients. The findings suggest that specific HLA alleles may reduce susceptibility or moderate the severity of COVID-19, indicating a need for broader genetic studies across diverse populations to validate these observations and improve management strategies for transplant recipients during pandemics.</AbstractText><CopyrightInformation>Copyright © 2024, Altundaş et al.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Altundaş</LastName><ForeName>Necip</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Balkan</LastName><ForeName>Eda</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Medical Biology, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kızılkaya</LastName><ForeName>Murat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Medical Biology, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Aksungur</LastName><ForeName>Nurhak</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kara</LastName><ForeName>Salih</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Korkut</LastName><ForeName>Ercan</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sevinç</LastName><ForeName>Can</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Öztürk</LastName><ForeName>Gürkan</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Atatürk University, Erzurum, TUR.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Cureus</MedlineTA><NlmUniqueID>101596737</NlmUniqueID><ISSNLinking>2168-8184</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">alleles</Keyword><Keyword MajorTopicYN="N">covid-19</Keyword><Keyword MajorTopicYN="N">hla</Keyword><Keyword MajorTopicYN="N">kidney</Keyword><Keyword MajorTopicYN="N">transplant</Keyword></KeywordList><CoiStatement>Human subjects: Consent was obtained or waived by all participants in this study. Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>7</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>7</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>27</Day><Hour>5</Hour><Minute>30</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>26</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39328629</ArticleId><ArticleId IdType="pmc">PMC11425025</ArticleId><ArticleId IdType="doi">10.7759/cureus.67881</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>COVID-19 and solid organ transplantation: a review article. Azzi Y, Bartash R, Scalea J, Loarte-Campos P, Akalin E. Transplantation. 2021;105:37–55.</Citation><ArticleIdList><ArticleId IdType="pubmed">33148977</ArticleId></ArticleIdList></Reference><Reference><Citation>An update on molecular diagnostics for COVID-19. Islam KU, Iqbal J. Front Cell Infect Microbiol. 2020;10:560616.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7683783</ArticleId><ArticleId IdType="pubmed">33244462</ArticleId></ArticleIdList></Reference><Reference><Citation>The MHC locus and genetic susceptibility to autoimmune and infectious diseases. Matzaraki V, Kumar V, Wijmenga C, Zhernakova A. Genome Biol. 2017;18:76.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5406920</ArticleId><ArticleId IdType="pubmed">28449694</ArticleId></ArticleIdList></Reference><Reference><Citation>Impact of HLA polymorphisms on the susceptibility to SARS-CoV-2 infection and related mortality in patients with renal replacement therapy. Akcay OF, Yeter HH, Unsal Y, Yasar E, Gonen S, Derici U. Hum Immunol. 2023;84:272–277.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9899785</ArticleId><ArticleId IdType="pubmed">36797091</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of HLA class I with severe acute respiratory syndrome coronavirus infection. Lin M, Tseng HK, Trejaut JA, et al. BMC Med Genet. 2003;4:9.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC212558</ArticleId><ArticleId IdType="pubmed">12969506</ArticleId></ArticleIdList></Reference><Reference><Citation>Association between HLA gene polymorphisms and mortality of COVID-19: an in silico analysis. Tomita Y, Ikeda T, Sato R, Sakagami T. Immun Inflamm Dis. 2020;8:684–694.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7654404</ArticleId><ArticleId IdType="pubmed">33047883</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA-B*44 and C*01 prevalence correlates with COVID-19 spreading across Italy. Correale P, Mutti L, Pentimalli F, Baglio G, Saladino RE, Sileri P, Giordano A. Int J Mol Sci. 2020;21:5205.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7432860</ArticleId><ArticleId IdType="pubmed">32717807</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA alleles associated with COVID-19 susceptibility and severity in different populations: a systematic review. Fakhkhari M, Caidi H, Sadki K. Egypt J Med Hum Genet. 2023;24:10.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9867832</ArticleId><ArticleId IdType="pubmed">36710951</ArticleId></ArticleIdList></Reference><Reference><Citation>Genetics insight for COVID-19 susceptibility and severity: a review. Fricke-Galindo I, Falfán-Valencia R. Front Immunol. 2021;12:622176.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8047200</ArticleId><ArticleId IdType="pubmed">33868239</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: a systematic review. Deb P, Zannat KE, Talukder S, Bhuiyan AH, Jilani MS, Saif-Ur-Rahman KM. HLA. 2022;99:281–312.</Citation><ArticleIdList><ArticleId IdType="pubmed">35067002</ArticleId></ArticleIdList></Reference><Reference><Citation>Infectious Diseases Society of America Guidelines on the Treatment and Management of Patients With COVID-19 (September 2022) Bhimraj A, Morgan RL, Shumaker AH, et al. Clin Infect Dis. 2024;78:0–349.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9494372</ArticleId><ArticleId IdType="pubmed">36063397</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA and AB0 polymorphisms may influence SARS-CoV-2 infection and COVID-19 severity. Amoroso A, Magistroni P, Vespasiano F, et al. Transplantation. 2021;105:193–200.</Citation><ArticleIdList><ArticleId IdType="pubmed">33141807</ArticleId></ArticleIdList></Reference><Reference><Citation>Association of HLA class I genotypes with severity of coronavirus disease-19. Shkurnikov M, Nersisyan S, Jankevic T, Galatenko A, Gordeev I, Vechorko V, Tonevitsky A. Front Immunol. 2021;12:641900.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7959787</ArticleId><ArticleId IdType="pubmed">33732261</ArticleId></ArticleIdList></Reference><Reference><Citation>Clinical characteristics and immunosuppressant management of coronavirus disease 2019 in solid organ transplant recipients. Zhong Z, Zhang Q, Xia H, et al. Am J Transplant. 2020;20:1916–1921.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7262295</ArticleId><ArticleId IdType="pubmed">32282986</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacrolimus use and COVID-19 infection in patients after solid organ transplantation. Yin S, Wang X, Song T. Gastroenterology. 2021;161:728–730.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7848533</ArticleId><ArticleId IdType="pubmed">33539863</ArticleId></ArticleIdList></Reference><Reference><Citation>Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study. Belli LS, Fondevila C, Cortesi PA, et al. Gastroenterology. 2021;160:1151–1163.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7724463</ArticleId><ArticleId IdType="pubmed">33307029</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA, immune response, and susceptibility to COVID-19. Tavasolian F, Rashidi M, Hatam GR, et al. Front Immunol. 2020;11:601886.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7820778</ArticleId><ArticleId IdType="pubmed">33488597</ArticleId></ArticleIdList></Reference><Reference><Citation>Polymorphism of HLA class I and class II alleles in influenza A(H1N1)pdm09 virus infected population of Assam, Northeast India. Dutta M, Dutta P, Medhi S, Borkakoty B, Biswas D. J Med Virol. 2018;90:854–860.</Citation><ArticleIdList><ArticleId IdType="pubmed">29315655</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA-A*11:01:01:01, HLA-C*12:02:02:01-HLA-B*52:01:02:02, age and sex are associated with severity of Japanese COVID-19 with respiratory failure. Khor SS, Omae Y, Nishida N, et al. Front Immunol. 2021;12:658570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8100314</ArticleId><ArticleId IdType="pubmed">33968060</ArticleId></ArticleIdList></Reference><Reference><Citation>HLA genetic polymorphisms and prognosis of patients with COVID-19. Lorente L, Martín MM, Franco A, et al. Med Intensiva. 2021;45:96–103.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7474921</ArticleId><ArticleId IdType="pubmed">38620408</ArticleId></ArticleIdList></Reference><Reference><Citation>Binding affinities of 438 HLA proteins to complete proteomes of seven pandemic viruses and distributions of strongest and weakest HLA peptide binders in populations worldwide. Barquera R, Collen E, Di D, et al. HLA. 2020;96:277–298.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7300650</ArticleId><ArticleId IdType="pubmed">32475052</ArticleId></ArticleIdList></Reference><Reference><Citation>Bioinformatic prediction of potential T cell epitopes for SARS-CoV-2. Kiyotani K, Toyoshima Y, Nemoto K, Nakamura Y. J Hum Genet. 2020;65:569–575.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7200206</ArticleId><ArticleId IdType="pubmed">32372051</ArticleId></ArticleIdList></Reference><Reference><Citation>Human leukocyte antigen susceptibility map for severe acute respiratory syndrome coronavirus 2. Nguyen A, David JK, Maden SK, Wood MA, Weeder BR, Nellore A, Thompson RF. J Virol. 2020;94:0–20.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7307149</ArticleId><ArticleId IdType="pubmed">32303592</ArticleId></ArticleIdList></Reference><Reference><Citation>IPD-IMGT/HLA database. Robinson J, Barker DJ, Georgiou X, Cooper MA, Flicek P, Marsh SG. Nucleic Acids Res. 2020;48:0–55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7145640</ArticleId><ArticleId IdType="pubmed">31667505</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>